

52	Magnesium sulfate	Magnesium sulfate	Magnesium mineral / magnesium oxide or hydroxide plus sulfuric acid
53	Meropenem	Meropenem	Protected carbapenem 4 AA nucleus plus pyrrolidinylthio side chain intermediate
54	Methylprednisolone	Methylprednisolone	Advanced corticosteroid / pregnane nucleus intermediate ; precise KSM depends on synthetic route
55	Metoprolol	Metoprolol	4 (2 methoxyethyl)phenol plus epichlorohydrin , followed by isopropylamine
56	Metronidazole	Metronidazole	2 methyl 5 nitroimidazole plus hydroxyethylating precursor
57	Micafungin	Micafungin sodium	FR901379 fermentation derived echinocandin intermediate , followed by semisynthetic side chain modification
58	Midazolam	Midazolam	Halogenated amino benzophenone / benzodiazepine ring precursor ; route specific
59	Morphine	Morphine sulfate / morphine	Poppy straw concentrate / opium derived morphine alkaloid stream
60	Naloxone	Naloxone	Thebaine / oxymorphone derived opiate intermediate
61	Nitroglycerin	Nitroglycerin	Glycerol plus nitric acid , with sulfuric acid process chemistry
62	Norepinephrine	Norepinephrine	Catechol derived amino alcohol / amino ketone intermediate
63	Ondansetron	Ondansetron	Carbazolone / carbazole intermediate plus imidazole containing side chain precursor ; route specific
64	Oxytocin	Oxytocin	Protected amino acids and peptide fragments used in solid phase or solution peptide synthesis
65	Pantoprazole	Pantoprazole	2 mercapto 5 difluoromethoxybenzimidazole plus substituted chloromethyl pyridine intermediate
66	Penicillin G	Benzylpenicillin	Fermentation organism plus phenylacetic acid side chain feedstock
67	Phenylephrine	Phenylephrine	3 hydroxy substituted acetophenone / amino alcohol precursor ; route specific
68	Phenytoin	Phenytoin	Benzil plus urea
69	Piperacillin / Tazobactam	Piperacillin; tazobactam	Piperacillin: 6 APA derived penicillin nucleus / ampicillin intermediate plus dioxopiperazine side chain . Tazobactam: penicillanic acid / 6 APA derived beta lactam nucleus
70	Potassium chloride	Potassium chloride	Potassium mineral brine / potash derived KCl ; no synthetic KSM in the conventional API sense
71	Propofol	Propofol	Phenol plus propylene / isopropylating feedstock to produce 2,6 diisopropylphenol
72	Rocuronium	Rocuronium bromide	Steroidal androstane nucleus intermediate ; exact KSM is route specific
73	Sodium bicarbonate injection	Sodium bicarbonate	Sodium carbonate plus carbon dioxide , or equivalent bicarbonate production process
74	Sodium phosphate	Sodium phosphate salts	Phosphoric acid plus sodium hydroxide / sodium carbonate
75	Succinylcholine	Succinylcholine chloride	Succinic acid / succinyl chloride derivative plus choline
76	Surfactant	Pulmonary surfactant	Product dependent : animal lung extract and phospholipids for animal derived products; defined phospholipids and peptide components for synthetic products
77	Tacrolimus	Tacrolimus	Streptomyces production strain, fermentation media, and downstream fermentation intermediate
78	Thiamine	Thiamine	Substituted pyrimidine intermediate plus thiazole intermediate
79	Ticagrelor	Ticagrelor	Triazolotriazine core intermediate plus chiral difluorophenyl cyclopentane fragment ; route specific
80	Topical / surface alcohol based sanitizers	Ethanol and/or isopropyl alcohol	Ethanol or isopropanol feedstock
81	Trimethoprim / Sulfamethoxazole	Trimethoprim; sulfamethoxazole	Trimethoprim: 3,4,5 trimethoxybenzaldehyde derived intermediate . Sulfamethoxazole: sulfonyl chloride aromatic intermediate plus 3 amino 5 methylisoxazole
82	Valganciclovir	Valganciclovir	Ganciclovir plus protected L valine derivative
83	Vancomycin	Vancomycin	Amycolatopsis production strain and fermentation inputs
84	Vasopressin	Vasopressin	Protected amino acids / peptide fragments used in peptide synthesis
85	Vitamin K	Phytonadione, vitamin K1	2 methyl 1,4 naphthoquinone / menadione related intermediate plus phytol side chain
86	Voriconazole	Voriconazole	Fluoropyrimidine / triazole containing chiral intermediates ; precise KSM is route specific

[FR Doc. 2026–19646 Filed 9–24–26; 8:45 am]

BILLING CODE 3110–01–C

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: 26–054]

Implementation of the Federal Civil Penalties Inflation Adjustment Act and Adjustment of Amounts for 2025—Continuation**AGENCY:** National Aeronautics and Space Administration.**ACTION:** Notice announcing no penalty inflation adjustment for civil monetary penalties for 2026.**SUMMARY:** The National Aeronautics and Space Administration (NASA) is notifying the public that its civil monetary penalty amounts will not increase for the 2026 calendar year. NASA is required by statute to amend its regulations annually to make

inflation adjustments to civil monetary penalties it assesses or enforces. In accordance with guidance from the Office of Management and Budget (OMB), NASA will continue to use the 2025 civil monetary penalty levels because there is no cost-of-living adjustment for 2026.

FOR FURTHER INFORMATION CONTACT: Bryan Diederich, bryan.r.diederich@nasa.gov, 202.358.0216.

SUPPLEMENTARY INFORMATION:

I. Background

The Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015 (the Inflation Adjustment Act) requires agencies to adjust civil monetary penalties annually for inflation. These adjustments are based on the Consumer Price Index for All Urban Consumers (CPI-U) for the month of October of the preceding year. For 2026, the Bureau of Labor Statistics did not publish the October 2025 CPI-U due to a lapse in appropriations. As a result, OMB Memorandum M-26-11 (April 17, 2026) directs agencies not to apply an inflation adjustment for 2026 and to continue using 2025 penalty levels.

II. No Adjustment for 2026

Consistent with the guidance provided in M-26-11, NASA is not making any adjustments to civil monetary penalties under the Inflation Adjustment Act in calendar year 2026.

Jamie M. Krauk,

*Director, Office of the Executive Secretariat,
National Aeronautics and Space
Administration.*

[FR Doc. 2026-19687 Filed 9-24-26; 8:45 am]

BILLING CODE 7510-13-P

**NUCLEAR REGULATORY
COMMISSION**

[Docket No. 50-289; EAXX-429-00-000-
1773009788; NRC-2026-0397]

**Constellation Energy Generation, LLC;
Christopher M. Crane Clean Energy
Center; Environmental Assessment
and Finding of No Significant Impact**

AGENCY: Nuclear Regulatory
Commission.

ACTION: Notice; issuance.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC), as the lead agency, and the U.S. Department of Energy (DOE) Office of Energy Dominance Financing (EDF), as a cooperating agency, are issuing an environmental assessment (EA) and finding of no significant impact (FONSI) evaluating the reasonably foreseeable

environmental effects from proposed Federal actions related to reauthorizing power operations at the Christopher M. Crane Clean Energy Center (CCEC). Specifically, the NRC is considering issuance of an exemption and three license amendments, which were requested by Constellation Energy Generation, LLC (CEG) to support the potential reauthorization of power operations at the CCEC. The DOE EDF's proposed action is a decision on providing Federal financial assistance (a loan guarantee) for refueling and resumption of power operations at the CCEC.

DATES: The EA and FONSI referenced in this document are available on September 25, 2026.

ADDRESSES: Please refer to Docket ID NRC-2026-0397 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document using any of the following methods:

- *Federal Rulemaking Website:* Go to <https://www.regulations.gov> and search for Docket ID NRC-2026-0397. Address questions about Docket IDs in *Regulations.gov* to Bridget Curran; telephone: 301-415-1003; email: Bridget.Curran@nrc.gov. For technical questions, contact the individuals listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- *NRC's Agencywide Documents Access and Management System (ADAMS):* You may obtain publicly available documents online in the ADAMS Public Documents collection at <https://www.nrc.gov/reading-rm/adams.html>. To begin the search, select "Begin ADAMS Public Search." For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, at 301-415-4737, or by email to PDR.Resource@nrc.gov. For the convenience of the reader, instructions about obtaining materials referenced in this document are provided in the "Availability of Documents" section.

- *NRC's PDR:* The PDR, where you may examine and order copies of publicly available documents, is open by appointment. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1-800-397-4209 or 301-415-4737, between 8 a.m. and 4 p.m. eastern time, Monday through Friday, except Federal holidays.

- *NRC Public Project Website:* The EA and FONSI along with information regarding the CCEC, including licensing, operation, decommissioning, and

potential restart, is available at <https://www.nrc.gov/info-finder/reactors/ccec>.

FOR FURTHER INFORMATION CONTACT:

Kevin Folk, telephone: 301-415-6944; email: Kevin.Folk@nrc.gov, or Ashley Waldron, telephone: 301-415-7317; email: Ashley.Waldron@nrc.gov. Both are staff of the Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.

SUPPLEMENTARY INFORMATION:

I. Introduction

The CCEC, formerly Three Mile Island Nuclear Station, Unit 1 (TMI-1), consists of a single pressurized-water nuclear reactor located in Dauphin County, Pennsylvania, on Three Mile Island in the Susquehanna River. Originally licensed for operation on April 19, 1974, the NRC issued a renewed facility operating license (RFOL) for TMI-1 on October 22, 2009, with the license term expiring on April 19, 2034.

On June 20, 2017, and September 26, 2019, Exelon Generation Company, LLC, the licensee who then operated the facility, submitted certifications that it would permanently cease operations of TMI-1 and had permanently removed fuel from the reactor vessel, respectively, in accordance with paragraph 50.82(a)(1) of title 10 of the *Code of Federal Regulations* (10 CFR). Upon the NRC's docketing of these certifications, the RFOL no longer authorized operation of the reactor or emplacement or retention of fuel into the reactor vessel, as provided by 10 CFR 50.82(a)(2).

CEG is seeking to return the CCEC to power operations and has submitted for NRC approval an exemption request and three license amendment requests (LARs) in support of allowing the resumption of power operations through April 19, 2034, the previous expiration date of the facility's RFOL.

A notice of opportunity to request a hearing and petition for leave to intervene was published in the **Federal Register** on February 24, 2026, regarding the three LARs. Consistent with the Atomic Energy Act of 1954, as amended (the Act), and the NRC's regulations, the NRC did not publish a notice of opportunity for hearing on the exemption request.

The NRC staff prepared a draft EA and draft FONSI in accordance with 10 CFR 51.30, "Environmental assessment," documenting its environmental review of the proposed actions related to reauthorizing power operations at the CCEC. The NRC staff issued the draft EA and draft FONSI with a notice in the